QbDVision Secures $15M to Revolutionize Drug Manufacturing with AI

QbDVision®, a digital platform for biopharma companies, has secured $15 million in Series A funding. The investment round was led by Northpond Ventures, with support from S3 Ventures, Wanxiang Healthcare Investments, and Hudson Park Capital. The company specialises in improving drug development through digital tools for chemistry, manufacturing, and controls (CMC).

The new funding will help QbDVision expand its technology and push forward its goal of modernising life science manufacturing. The platform focuses on increasing efficiency in CMC operations, a critical part of pharmaceutical production.

Northpond Ventures took the lead in the investment, joined by previous backers and new contributors. The company aims to use the capital to enhance its software and broaden its impact on the biopharma industry.

QbDVision's mission centres on driving digital transformation in drug manufacturing. By streamlining processes, it hopes to reduce delays and improve quality in pharmaceutical production.

The $15 million investment will support QbDVision's growth and its efforts to shape the future of biopharma manufacturing. The company plans to use the funds to refine its platform and expand its reach within the industry. This move follows a growing trend of digital adoption in life sciences.